Arvinas Estrogen Receptor
CompanyUnited States
Arvinas Estrogen Receptor develops one asset, in phase 1 (ARV-471 in breast cancer). Mostly small molecule acting on proteostasis and ESR1; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 1
- 2
- Trials
- 0
- Signals
Pipeline
1Estrogen receptor PROTAC degrader for treating estrogen receptor-positive breast cancer.
Phase 1, Small molecule, Proteostasis, ESR1, breast cancer
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials6
- Similar companies6